The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial
Open accessAbstract
BACKGROUND: Breast cancer becomes lethal when visceral metastases develop. At this stage, anti-cancer treatments aim at relieving symptoms and delaying death without resulting in additional toxicity. On the basis of their differential anti-oxidant defence level, tumour cells can be made more sensitive to chemotherapy than non-tumour cells when membrane lipids are enriched with docosahexaenoic acid (DHA), a peroxidisable and oxidative-stress-inducing lipid of marine origin. METHODS: This open-label single-arm phase II study evaluated the safety and efficacy (response rate), as primary end points, of the addition of 1.8 g DHA daily to an anthracycline-based chemotherapy (FEC) regimen in breast cancer patients (n = 25) with rapidly progressing visceral metastases. The secondary end points were time to progression (TTP) and overall survival (OS). RESULTS: The objective response rate was 44%. With a mean follow-up time of 31 months (range 2-96 months), the median TTP was 6 months. Median OS was 22 months and reached 34 months in the sub-population of patients (n = 12) with the highest plasma DHA incorporation. The most common grade 3 or 4 toxicity was neutropaenia (80%). CONCLUSION: DHA during chemotherapy was devoid of adverse side effects and can improve the outcome of chemotherapy when highly incorporated. DHA has a potential to specifically chemosensitise tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Distribution, interconversion, and dose response of n-3 fatty acids in humans.
Arterburn, L. M., Hall, E. B., & Oken, H. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1467s · Cited by 1,162
Gehan, E. A. (1961) · Journal of Chronic Diseases · doi:10.1016/0021-9681(61)90060-1 · Cited by 667
Adriamycin-induced heart failure: mechanisms and modulation
Singal, P., Li, T., Kumar, D., Danelisen, I., & Iliskovic, N. (2000) · Molecular and Cellular Biochemistry · doi:10.1023/a:1007094214460 · Cited by 428
Metabolism of α-linolenic acid in humans
Burdge, G. C. (2006) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2006.05.013 · Cited by 388
Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol.
Olson, R. D., Mushlin, P. S., Brenner, D. E., Fleischer, S., Cusack, B. J., Chang, B. K., & Boucek, R. J. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.10.3585 · Cited by 357
Vidgren, H. M., Ågren, J. J., Schwab, U., Rissanen, T., Hänninen, O., & Uusitupa, M. I. J. (1997) · Lipids · doi:10.1007/s11745-997-0089-x · Cited by 236 · cited 1×
“Although DHA is a non-toxic compound (Kroes et al, 2003), its incorporation into blood cell precursors (Vidgren et al, 1997) theoretically could have resulted in an increased myelosuppression during its prolonged association (16 to 22 weeks) with FEC chemotherapy.”
BackgroundLysophosphatidylcholine as a Preferred Carrier Form of Docosahexaenoic Acid to the Brain
Lagarde, M., Bernoud, N., Brossard, N., Lemaitre-Delaunay, D., Thiès, F., Croset, M., & Lecerf, J. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:16:2-3:201 · Cited by 221
Cited by
ESPEN guidelines on nutrition in cancer patients
Arends, J., Bachmann, P., Baracos, V., Barthelemy, N., Bertz, H., Bozzetti, F., Fearon, K., Hütterer, E., Isenring, E., Kaasa, S., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2016.07.015 · Cited by 3,114
Record, M., Carayon, K., Poirot, M., & Silvente-Poirot, S. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.10.004 · Cited by 852
Omega-3 long-chain polyunsaturated fatty acids and aquaculture in perspective
Tocher, D. R. (2015) · Aquaculture · doi:10.1016/j.aquaculture.2015.01.010 · Cited by 769
Oxidative stress injury in doxorubicin-induced cardiotoxicity
Songbo, M., Lang, H., Xinyong, C., Bin, X., Ping, Z., & Liang, S. (2019) · Toxicology Letters · doi:10.1016/j.toxlet.2019.02.013 · Cited by 566
Very long-chain n -3 fatty acids and human health: fact, fiction and the future
Calder, P. C. (2018) · Proceedings of the Nutrition Society · doi:10.1017/s0029665117003950 · Cited by 419
Metadata
- Authors
- Bougnoux, P., Hajjaji, N., Ferrasson, M. N., Giraudeau, B., Couet, C., & Le Floch, O.
- Venue
- British Journal of Cancer
- Published
- 2009-11-17
- Volume
- 101
- Issue
- 12
- Pages
- 1978-1985
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2048647257
- Cited by
- 264
- References
- 30
- FWCI
- 13.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. https://app.cochat.ai/papers/10.1038/sj.bjc.6605441
- The paper
- Bougnoux, P., Hajjaji, N., Ferrasson, M. N., Giraudeau, B., Couet, C., & Le Floch, O. (2009). Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6605441
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.